Resverlogix Corp logo

Resverlogix Corp

NEW
TSX:RVX (Canada)  
C$ 0.06 (-8.33%) Dec 13
At Loss
Market Cap:
C$ 15.44M ($ 10.85M)
Enterprise V:
C$ 28.10M ($ 19.74M)
Volume:
53.30K
Avg Vol (2M):
64.52K
Trade In:
Volume:
53.30K
At Loss

Business Description

Description
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 0.01
Equity-to-Asset -10.7
Debt-to-Equity -0.11
Debt-to-EBITDA -1.1
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EPS without NRI Growth Rate 29.8
3-Year FCF Growth Rate 49
3-Year Book Growth Rate 4.8

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 33.37
9-Day RSI 40.82
14-Day RSI 43.12
6-1 Month Momentum % 20
12-1 Month Momentum % -14.29

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.08
Quick Ratio 0.04

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -8.8
Shareholder Yield % -10.56

Profitability Rank

Name Current Vs Industry Vs History
ROA % -151.63
ROIC % -50.02
3-Year ROIIC % -106.93
ROC (Joel Greenblatt) % -6373.48
Years of Profitability over Past 10-Year 1

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT -2.44
EV-to-EBITDA -2.56
EV-to-FCF -5.09
Earnings Yield (Greenblatt) % -40.98
FCF Yield % -35.73

Financials (Next Earnings Date:2025-02-12 Est.)

TSX:RVX's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Resverlogix Corp Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil C$)
EPS (TTM) (C$) -0.063
Beta 0.96
3-Year Sharpe Ratio -0.55
3-Year Sortino Ratio -0.82
Volatility % 98.43
14-Day RSI 43.12
14-Day ATR (C$) 0.003546
20-Day SMA (C$) 0.0575
12-1 Month Momentum % -14.29
52-Week Range (C$) 0.04 - 0.095
Shares Outstanding (Mil) 280.65

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 1
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Resverlogix Corp Filings

Filing Date Document Date Form
No Filing Data

Resverlogix Corp Stock Events

Financials Calendars
Event Date Price (C$)
No Event Data

Resverlogix Corp Frequently Asked Questions

What is Resverlogix Corp(TSX:RVX)'s stock price today?
The current price of TSX:RVX is C$0.06. The 52 week high of TSX:RVX is C$0.10 and 52 week low is C$0.04.
When is next earnings date of Resverlogix Corp(TSX:RVX)?
The next earnings date of Resverlogix Corp(TSX:RVX) is 2025-02-12 Est..
Does Resverlogix Corp(TSX:RVX) pay dividends? If so, how much?
Resverlogix Corp(TSX:RVX) does not pay dividend.

Press Release

Subject Date
No Press Release